Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
Piet Ost on X: "What might PSMA PET-CT do in high risk PCa with its improved accuracy? It results in stage migration, mostly in the direction of finding more disease. How do
Prostate Cancer: Double VS triplet therapy in mHSPC - Urology Cheatsheets
Frontiers | Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
ASCO GUIDELINES Bundle - Noncastrate Advanced, Recurrent or Metastatic Prostate Cancer Initial Management
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference
Current Oncology | Free Full-Text | Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
Computed Tomography (CT) and Bone Scans (BS) for Hormone Sensitive Prostate Cancer
VIDEO: Poly-Metastatic Hormone-Sensitive Disease - Prostate Cancer Patient Conference 2022 - UCTV - University of California Television
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
Surgical management of high-risk, localized prostate cancer | Nature Reviews Urology
Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article) | Published in International Journal of Cancer Care and Delivery
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer | Swiss Medical Weekly
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand | Bentham Science
Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? - ScienceDirect
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England | Prostate Cancer and Prostatic Diseases
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer - ScienceDirect
Prostate | Radiology Key
Page 27 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
